Wockhardt LimitedNSE: WOCKPHARMA

Press Release Jan 02 2025

· Issued by Wockhardt Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Wockhardt Limited has announced that the Indian drug regulator has approved its new oral antibiotic Miqnaf for treating community-acquired bacterial pneumonia. This approval follows a favorable recommendation from the Subject Expert Committee of the Central Drugs Standard Control Organization. Miqnaf is designed as a short, once-a-day treatment that addresses antibiotic resistance issues in pneumonia cases. Wockhardt plans to launch Miqnaf in the Indian market in the coming months.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Wockhardt Limited has informed the Exchange regarding a press release dated January 02, 2025, titled "Indian Drug Regulator Approves Wockhardt's New Generation Oral Antibiotic Miqnaf? (Nafithromycin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)."

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases